NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a developer of adult stem cell technologies and therapeutics, today provided a review of recent accomplishments for shareholders and investors.
Since the beginning of the Phase I/II clinical trial for BrainStorm’s autologous adult stem cell therapy at the Hadassah Medical Center, significant progress has been made towards achieving the goals of enrolling and treating patients with amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig’s Disease.
